- Home
- ADAP
as 07-01-2024 4:00pm EST
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
| Founded: | 2008 | Country: | United Kingdom |
| Employees: | N/A | City: | ABINGDON, OXFORDSHIRE |
| Market Cap: | 212.5M | IPO Year: | 2015 |
| Target Price: | $4.29 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.42 - $2.05 | Next Earning Date: | 08-07-2024 |
| Revenue: | $18,358,000 | Revenue Growth: | -74.21% |
| Revenue Growth (this year): | 4.87% | Revenue Growth (next year): | -24.42% |
Stock Insider Trading Activity of Adaptimmune Therapeutics plc (ADAP)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Piccina Cintia | ADAP | Chief Commercial Officer | Jun 18 '24 | Sell | $0.93 | 24,531 | $22,813.83 | 38,293 | SEC Form 4 |
| Rawcliffe Adrian | ADAP | Chief Executive Officer | Jan 16 '24 | Sell | $0.79 | 9,304 | $7,350.16 | 14,104 | SEC Form 4 |
| Rawcliffe Adrian | ADAP | Chief Executive Officer | Jan 16 '24 | Sell | $0.67 | 30,080 | $20,243.84 | 44,848 | SEC Form 4 |
| Lunger John | ADAP | Chief Patient Supply Officer | Jan 16 '24 | Sell | $0.79 | 4,681 | $3,697.99 | 7,023 | SEC Form 4 |
| Lunger John | ADAP | Chief Patient Supply Officer | Jan 16 '24 | Sell | $0.67 | 5,309 | $3,572.96 | 7,785 | SEC Form 4 |
| Lunger John | ADAP | Chief Patient Supply Officer | Jan 16 '24 | Sell | $0.67 | 12,805 | $8,617.77 | 19,015 | SEC Form 4 |
| Bertrand William C JR | ADAP | Chief Operating Officer | Jan 16 '24 | Sell | $0.79 | 4,681 | $3,697.99 | 7,023 | SEC Form 4 |
| Bertrand William C JR | ADAP | Chief Operating Officer | Jan 16 '24 | Sell | $0.67 | 5,309 | $3,572.96 | 7,785 | SEC Form 4 |
| Bertrand William C JR | ADAP | Chief Operating Officer | Jan 16 '24 | Sell | $0.67 | 13,599 | $9,152.13 | 20,201 | SEC Form 4 |
| Norry Elliot | ADAP | Chief Medical Officer | Jan 11 '24 | Sell | $0.85 | 7,799 | $6,661.13 | 11,841 | SEC Form 4 |
| Norry Elliot | ADAP | Chief Medical Officer | Jan 11 '24 | Sell | $0.84 | 4,009 | $3,354.33 | 6,104 | SEC Form 4 |
| Bertrand William C JR | ADAP | Chief Operating Officer | Jan 11 '24 | Sell | $0.84 | 4,009 | $3,354.33 | 6,104 | SEC Form 4 |
| Bertrand William C JR | ADAP | Chief Operating Officer | Jan 11 '24 | Sell | $0.85 | 5,220 | $4,458.40 | 7,874 | SEC Form 4 |
| Rawcliffe Adrian | ADAP | Chief Executive Officer | Jan 11 '24 | Sell | $0.84 | 11,945 | $9,994.38 | 18,395 | SEC Form 4 |
| Rawcliffe Adrian | ADAP | Chief Executive Officer | Jan 11 '24 | Sell | $0.85 | 17,257 | $14,739.20 | 26,388 | SEC Form 4 |
| Lunger John | ADAP | Chief Patient Supply Officer | Jan 11 '24 | Sell | $0.84 | 4,009 | $3,354.33 | 6,104 | SEC Form 4 |
| Lunger John | ADAP | Chief Patient Supply Officer | Jan 11 '24 | Sell | $0.85 | 5,220 | $4,458.40 | 7,874 | SEC Form 4 |
Latest Adaptimmune Therapeutics plc News
ADAP Breaking Stock News: Dive into ADAP Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
20 days ago
ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company
Yahoo Finance Video
22 days ago
FDA panel votes to recommend Eli Lilly's Alzheimer's drug
GlobeNewswire
22 days ago
Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis
Reuters
22 days ago
California seeks company profits in Big Oil climate lawsuit
USA TODAY
22 days ago
S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead
GlobeNewswire
22 days ago
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
Business Wire
22 days ago
Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock
Business Wire
22 days ago
Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas
Share on Social Networks:
Disclaimer
The information presented on this page, "ADAP Adaptimmune Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.